Document:

<PAGE>

                                                                    EXHIBIT 10.3

                             EMPLOYMENT AGREEMENT

  THIS EMPLOYMENT AGREEMENT ("Agreement") is made and entered into effective the
1st day of November, 2000 by and between SeraCare, Inc. (referred herein as the
"Corporation") and Michael F. Crowley II ("Crowley").

  1.      Employment as President of SeraCare Life Sciences, Inc., a wholly
owned subsidiary of SeraCare, Inc.  The Corporation hereby agrees to retain
Crowley and Crowley hereby agrees to be employed as President of SeraCare Life
Sciences, Inc.  In the performance of his duties and responsibilities, Crowley
shall at all times be under the direction of the President of the Corporation.
Crowley shall perform his duties and responsibilities in accordance with
reasonable rules, regulations and policies of the Corporation.

  2.      Extent of Services.  Crowley agrees to devote all of his efforts on
behalf of the business of the Corporation.  Without limiting the foregoing,
during the term of this Agreement, Crowley shall not, directly or indirectly,
either as an employee, consultant, stockholder or in any other capacity, engage
or participate in any business that is in competition in any manner with the
Corporation.

  3.      Indemnification; Insurance Agreement.  The Corporation warrants and
assures Crowley that the Charter of the Corporation contains a provision which
provides for indemnification of officers by the Corporation and to the maximum
extent permissible under the laws of the jurisdiction in which the Corporation
is incorporated.  Further, the Corporation agrees to either or both of the
following:

          A.  Enter into an Indemnification Agreement provided that such
  Indemnification Agreement shall be modified if necessary to conform with the
  laws of the jurisdiction in which the Corporation is incorporated.

          B.  Obtain and maintain in full force and effect at Corporation's sole
  expense, such director's and officer's liability insurance for errors and
  omissions of such type and in such amount as is customary for similarly
  situated companies, if available at reasonable cost.

  4.      No Competing Affiliations.  During the term of this agreement, Crowley
will not serve as a consultant, employee or other paid assistant or in any like
role or capacity with any other competing or potentially competing company with
like operations, business strategies, or objectives.  In addition, for a period
of two years after termination of this agreement Crowley may work within the
industry but shall not engage in any employment or activities which are or could
reasonably be expected to have an adverse affect upon the operations of the
Corporation.

  5.      Compensation.  Beginning with the pay period beginning on November 1,
2000, Crowley shall be compensated at the rate of $145,000 per year.  In
addition, Crowley shall receive an Option to purchase 40,000 of the
Corporation's common shares at a price of $3.00 per share.  Such Option fully
vest on February 28, 2003.

                                      -1-
<PAGE>

     6.   Performance Bonus.  Crowley shall also qualify to receive a bonus of
$50,000 for each of fiscal years 2002 and 2003 if SeraCare Life Sciences, Inc.
equals or exceeds budgeted net income for such years.  The budgets will be
established jointly by Crowley, the President of the Corporation and the Chief
Financial Officer of the Corporation.

     7.   Fringe Benefits.  Crowley shall receive four (4) weeks paid vacation
per year during the course of this Agreement.  Crowley will also receive company
paid:  sick pay, group health insurance, dental care, vision care, disability
insurance, life insurance and such other benefits in the amount and as may be
provided in the ordinary course to the Corporation's other executives.

     8.   Term.  This Agreement shall be for the twenty-eight month period
beginning on November 1, 2000 and ending on February 28, 2003.

     9.   Termination.

          9.1   Termination for Cause.  The Corporation may terminate this
Agreement immediately and without notice for cause.  "Cause" for the purpose of
this agreement shall include, but not be limited to:  death; dishonesty; theft;
conviction of a felony; alcohol or drug abuse; unethical business conduct; and a
material breach of this Agreement by Crowley.  "Cause" shall also include the
failure of Crowley for any reason, within ten days after receipt by Crowley of
written notice thereof from the President and/or Board of Directors, to cease or
otherwise alter any insubordination, failure to comply with instructions, or
other action or omission to act which, in the sole opinion of the President of
the Corporation, materially affects or could materially affect the Corporations'
business operations.  Other events which will result in the termination of this
Agreement are:

          A.    The date on which Crowley agrees to terminate this Agreement.

          B.    The disability of Crowley. Disability herein is defined as being
     unable to perform the duties hereunder due to a physical and/or mental
     condition or impairment for ninety (90) cumulative days during the term of
     this Agreement or sixty (60) consecutive days in any three hundred sixty-
     five (365) day period.

          C.    The date on which Crowley voluntarily ceases to perform his
     duties hereunder, other than by reason of a physical or mental condition
     prior to the time that a disability occurs.

If this agreement is terminated for "Cause" as herein defined, Crowley shall not
be entitled to any termination or severance payments.

          9.2   Termination for Without Cause.  If this Agreement is terminated
by the Corporation for any reason other than "Cause" as herein defined, Crowley
shall be entitled to receive the balance of the amount due under this Agreement.
Such payments shall be payable in accordance with the normal payroll cycle over
the remaining term of this Agreement.

     10.  No Solicitation of Employees.  During the period of this Agreement and
for two (2) full years following termination of this Agreement, Crowley shall
not, for any reason either

                                      -2-
<PAGE>

directly or indirectly, solicit for employment or employ for any other entity
any employee of the Corporation.

     11.  Withholding.  Crowley authorizes the Corporation to withhold and/or
deduct from his compensation (including, without limitation, salary and wages),
deductions to recover any amounts loaned by the Corporation to Crowley or paid
on Crowley's behalf which, under the terms of said loan or payment, must be
repaid to the Corporation including, without limitation, loans of money and the
value of any of the Corporations property taken but not returned by Crowley.
Corporation shall also have the expressed right to deduct all sums required for
federal, sate or local income, Social Security or other taxes now applicable or
that may be enacted in the future.

     12.  Notice.  Any notice provided to be given pursuant to this Agreement
shall be in writing and shall be deemed duly given three days after deposited in
the mail, certified mail, return receipt requested, to the party to receive such
notice at the address specified below:

          The Corporation:         SeraCare Life Sciences, Inc.
                                   1925 Century Park East, Suite 1970
                                   Los Angeles, CA  90067

          For Crowley:             Michael F. Crowley II
                                   569 Anchorage Avenue
                                   Carlsbad, CA  92009

     13.  Governing Law.  The validity of this Agreement and the interpretation
and performance of all of its terms shall be controlled exclusively by the
substantive law of California, including California law concerning the
interpretation and performance of contracts.

     14.  Enforceability.  Any provision of this Agreement which is invalid,
illegal, or unenforceable shall be ineffective only to the extent of such
invalidity, illegality, or unenforceability, without affecting in any way the
remaining provisions hereof or rendering the remaining provisions hereof
invalid, illegal, or unenforceable.

     15.  Waiver.  The failure of either party hereto to insist upon strict
compliance with any of the terms, covenants or conditions of this Agreement by
the other party shall not be deemed a waiver of that or any other term,
covenant, or condition, nor shall any waiver or relinquishment of any right or
power at any one time or times be deemed a waiver or relinquishment of that
right or power for all or any other times.

     16.  Trade Secrets, Confidential and Proprietary Information.

          A.  Crowley and Corporation acknowledge and agree that during the term
     of this agreement and in the course of the discharge of his duties
     hereunder, Crowley shall have access to and become acquainted with
     information owned by the Corporation concerning its operation, which
     information derives independent economic value from not being generally
     known to the public or competitors, and which includes, without limitation:
     (1) manufacturing process, research and engineering, (2) marketing data and
     techniques, (3) trademarks, tradenames, and servicemarks, (4) customer and
     client bases

                                      -3-
<PAGE>

     and lists, and (5) financial and personnel information. Said information
     constitutes Employer's trade secret, confidential and proprietary
     information.

          B.  Crowley agrees that he shall not at any time (during the period of
     this agreement or any future time) disclose such trade secret,
     confidential, or proprietary information, directly or indirectly, to any
     other person or use it in any way other than as required in the ordinary
     course of his employment under this agreement.

          C.  Crowley further agrees that all files, records, documents,
     equipment and similar items relating to the Corporations business
     (including, without limitation, items containing trade secret, confidential
     or proprietary information), whether prepared by Crowley or others,
     including all origins and copies, are and shall be returned to the
     Corporation upon Crowley's termination.

          D.  Crowley further agrees that during the period of his employment by
     the Corporation and after termination thereof, he will not disrupt, damage,
     disparage, impair, or interfere with the Corporation's business or its
     reputation, whether by way of interfering with or soliciting its employees,
     disrupting its relationships with or soliciting clients or customers,
     agents, representatives, or vendors, aiding competitors, or by way of any
     other conduct.

     17.  Non-Assignability.  Crowley may not assign any of his rights or
responsibilities under this Agreement.

     18.  Entire Agreement.  This Agreement supersedes any and all other
agreements, either oral or in writing, between the parties hereto with respect
to the employment of Crowley by the Corporation and contains all of the
covenants and agreements between the parties with respect to that employment in
any manner whatsoever.  Each party to this Agreement acknowledges that no
representation, inducements, promises, or agreements, orally or otherwise, have
been made by any party, or anyone acting on behalf of any party, which are not
embodied herein, and that no other agreement, statement, or promise not
contained in this Agreement shall be valid or binding on either party.

     19.  Modifications.  Any modification of this Agreement shall be effective
only if it is in writing and signed by both parties to this Agreement.

     IN WITNESS WHEREOF, the parties hereto do hereby authorize and acknowledge
that this Agreement be the effective agreement between the parties.

     SeraCare Life Sciences, Inc.:    Michael F. Crowley II:

     By:  /s/ Barry D. Plost          By:  /s/ Michael F. Crowley II
          ------------------               -------------------------
          Barry D. Plost                   Michael F. Crowley II
          President and CEO                An individual

                                      -4-<PAGE>

                                                                    EXHIBIT 10.4

                                                                REDACTED VERSION

                           ALBUMIN SUPPLY AGREEMENT

     *** Confidential treatment has been requested as to certain portions of
     this agreement. Such omitted confidential information has been designated
     by an asterisk and has been filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange
     Act of 1934, as amended, and the Commission's rules and regulations
     promulgated under the Freedom of Information Act, pursuant to a request for
     confidential treatment. ***

In Barcelona on this 22 day of June 1999.

                                BY AND BETWEEN

SERACARE INC., a corporation of USA nationality, with address at 1926 Century
Park East, Suite 1970, Los Angeles, California, USA, represented by Mr. Barry D.
Plost, by virtue of his position as Chairman/CEO (hereinafter referred to as
SERACARE), party to the first part.

INSTITUTO GRIFOLS, S.A., a corporation of Spanish nationality, with address at
Poligono Industrial Levante, Calle Can Guasch, s/n. 08150 Parets del Valles,
Barcelona, Spain, represented by Mr. Javier Jorba Ribes, by virtue of his
position as General Manager, (Hereinafter referred to as GRIFOLS), party of the
second part.

                                    WHEREAS

I.   SERACARE is a corporation, which main activity is as a collector of plasma,
     distributor of therapeutic and diagnostic plasma derived products, and as a
     manufacturer of diagnostic products.

                                       1
<PAGE>

II.   GRIFOLS is a corporation, which main activity is the manufacturing and
      commercialization of Hemoderivatives, including Human Albumin, which are
      manufactured in it premises located in Parets del Valles.

III.  GRIFOLS declares that its Human Albumin complies with the technical
      specifications that are detailed in Annex 1 attached hereto, and has all
      the necessary and required permits.

IV.   That both parties know that GRIFOLS Human Albumin is manufactured for
      its direct use and only in accordance with the product indications
      described in Annex 2 attached hereto.

V.    GRIFOLS is willing to supply and SERACARE to acquire, Human Albumin
      (hereinafter referred to as Albumin), due to which, both parties
      recognizing in each other enough legal capacity, agree to enter into the
      present Albumin Supply Agreement in accordance with the following.

                                    CLAUSES

FIRST -  Constitutes the object of the present Agreement, the supply to SERACARE
-------
of Human Albumin manufactured by GRIFOLS, to be sold by SERACARE to third
parties, which may only use said Human Albumin as raw material in its production
of certain products, and never for direct use, in accordance with the provisions
of this Agreement.

                                       2
<PAGE>

SECOND -  Due to the special technical specifications and quality controls that
--------
the Albumin has to comply with, the parties agree that all the Albumin supplied
by GRIFOLS to SERACARE will have a certified batch release from GRIFOLS.

THIRD -  The Albumin supplied by GRIFOLS to SERACARE will be used by any third
-------
party only as raw material, for the purpose of manufacturing products listed in
Annex 3.  No other use different from this, including its human use, is covered
by the present Agreement.

The Albumin supplied by GRIFOLS to SERACARE will not be mixed in the
manufacturing process of the products listed in Annex 3 carried out by any third
party with any other product of human origin.

GRIFOLS shall have the right, with prior notification of 24 hours, to require
SERACARE to inspect any third parties' manufacturing facilities and records in
order to verify the correct use of the Albumin supplied/sold by SERACARE to this
third party in accordance with the provisions of the present Agreement.

FOURTH -  The quality and technical specifications of the Albumin supplied by
--------
GRIFOLS to SERACARE, as detailed in Annex 1.

The quality and technical specifications, may be changed and/or modified, at
GRIFOLS' requirement, in order to comply with any new legislation in force
and/or new controls or test methods.  Any change carried out in accordance will
be duly notified to SERACARE, which shall notify it to all third parties to whom
the Albumin has been supplied/sold.

                                       3
<PAGE>

Every shipment of Albumin will be shipped together with all the mandatory and/or
legal documents, as well as any other documents that may be required.

FIFTH -  SERACARE will acquire from GRIFOLS the annual quantities established in
-------
Annex 4.  Both parties, on a yearly basis, will fix these minimum annual
quantities, as well as the Product price, which will also be included in said
Annex.

In the event that / new test and/or control is required, as stated in Clause
Fifth hereinabove, GRIFOLS and SERACARE shall mutually agree to renegotiate the
prices set forth in this Agreement.

SIXTH -  Payment of the Albumin delivered by GRIFOLS to SERACARE would be
-------
payable 30 days after reception by SERACARE in its premises in Oceanside, CA,
USA.

SEVENTH -  The Albumin will be shipped and packed in accordance with the
---------
specifications set forth in Annex 5 to the present Agreement.

EIGHTH -  For the event that the Albumin supplied by GRIFOLS to SERACARE is
--------
object of a product recall carried out by GRIFOLS, GRIFOLS will be responsible
only for its reposition with new Albumin.

Due to the use that third parties shall give to the Albumin, which will be as
raw material for manufacturing products listed in Annex 3 which is different and
not specified in the Product indications given by GRIFOLS, SERACARE and/or any
third party will be solely responsible for its use in accordance with the
present Agreement, and will hold GRIFOLS harmless of any

                                       4
<PAGE>

circumstances derived from the use that SERACARE and/or any third party will
give to the Albumin.

NINTH -  SERACARE declares that it has a product liability insurance covering
-------
the products, for an amount of $US 5,000,000 and takes the commitment to have
such insurance coverage while the present Agreement is in force and the products
manufactured using the Albumin have not expired, and will also require that any
third party using the Albumin has a product liability insurance in the same
terms and conditions.

TENTH -  All information disclosed by GRIFOLS to SERACARE concerning any aspect
-------
of Albumin, including discussions with Regulatory Authorities, shall be
considered as Confidential Information under this Agreement.

The party receiving the Confidential Information:

1.   Will not disclose the Confidential Information to any third party, except
     as required by the Regulatory Authorities strictly for the purposes of this
     Agreement.

2.   Will limit disclosure of the Confidential Information to its employees and
     agents who, under obligation of confidentiality, have a need to know of it
     for the purposes of this Agreement.

3.   Will make no use of the received Confidential Information other than to
     fulfill the purposes of this Agreement.

                                       5
<PAGE>

4.   On termination of this Agreement, will return all such Confidential
     Information to the disclosing party, without retaining any copy or extract
     thereof.

The following will be exempt from the obligation of this Article:

a)   Confidential Information which is now, or which becomes, part of the public
     domain without involvement of the receiving party.

b)   Confidential Information which the receiving party can demonstrate by
     competent proof was known to it before being received from the disclosing
     party.

c)   Confidential Information which becomes available to the receiving party
     from a third party under no obligation of confidentiality to the disclosing
     party.

The obligations of this article shall continue after termination of this
Agreement.

ELEVENTH -  SERACARE shall, prior to any sale of Albumin to any third party,
----------
inform GRIFOLS of the identity of said third party, as well as sign an agreement
with this third party that shall cover the following:

-    Use that this third party may do of the Albumin, which is as detailed in
     the manufacturing of products listed in Annex 3.

-    Manufacturing information by which this third party has to inform SERACARE
     and GRIFOLS of the lot numbers of the products manufactured using GRIFOLS
     Albumin.

-    Product liability insurance as foreseen in Clause Ninth of the present
     Agreement.

                                       6
<PAGE>

-    Signature of a Confidential Disclosure Agreement between said third party
     and GRIFOLS, which will be that attached as enclosure 6 hereto.

-    Responsibility Clause identical to that foreseen in Clause Eighth of the
     present Agreement.

-    Force Majeure Clause identical to that foreseen in Clause Thirteenth of the
     present Agreement.

-    Rescission/termination clause, which covers any breach of the clauses of
     the Agreement by the third party, especially if the Albumin is not used as
     raw material in the manufacturing of products listed in Annex 3, and a
     different use is given to it.

-    Clause including that SERACARE shall have the right, with a prior
     notification of 24 hours, to inspect the third parties' manufacturing
     facilities and records, in order to verify the correct use of the Albumin
     supplied by GRIFOLS in accordance with the provisions of the present
     Agreement.

TWELFTH -  The duration of the present Agreement will be until 31/st/ December
---------
1999, and will start on the date of its signature.  The Agreement will be
automatically renewed for one-year periods if neither party denounces it three
months before its expiry.

THIRTEENTH -  Neither party shall be liable for non-performance of this
------------
Agreement due to Force Majeure.  Force Majeure will have the meaning stated
below under (a):

                                       7
<PAGE>

a)   Strikes, lockouts, other industrial disturbances, rebellions, mutinies,
     epidemics, landslides, lightning, earthquakes, fires, storms, floods,
     sinking, drought, civil disturbances, explosions, act or decisions of duly
     constituted municipal, state or National Governmental Authorities or of
     Courts of Law, impossibility to obtain supplies, fuel or other required
     materials, or any other causes similar or completely different, all beyond
     the control of the Party pleading Force Majeure preventing the Party from
     performing its rights and obligations and not to be overcome by due
     diligence of such Party.

b)   The Parties agree that if either of them find themselves wholly or partly
     unable to fulfill their respective obligations in this Agreement by reason
     of Force Majeure, the Party pleading Force Majeure will as soon as possible
     notify the other Party of its inability to perform giving detailed
     explanation of the occurrence which excuses performance.  If said notice is
     given, the performance of the notifying party shall be abated for so long
     as performance may be prevented by Force Majeure.  A Party unable to
     perform due to Force Majeure shall resume fulfilling its obligations,
     including making the due payments, after the Force Majeure has ceased.  All
     terms will be extended by the time period the Force Majeure has lasted.

FOURTEENTH -  The present Agreement will be terminated and will become null due
------------
to any of the following reasons:

a)   Mutual agreement.

b)   Those fixed by law.

                                       8
<PAGE>

c)   With thirty (30) days notice if the other party shall default in the
     performance or observation of any material provisions of this Agreement and
     shall fail to cure such default within sixty (60) days after notice from
     such party, and the non-defaulting party shall reserve a right to seek a
     remedy available under the applicable laws.

d)   If any party falls into suspension of payments or becomes bankrupt.

e)   Not meeting payments due.

f)   Any substantial change in the ownership in any of the parties which may
     give rise to a change in the political control of the Company, or the
     participation through the acquisition of shares by a direct competitor of
     any of the parties.

FIFTEENTH -
-----------

a)   Any notice required or provided for by the terms of this Agreement shall be
     made in writing and shall be sent by registered mail postage prepaid or by
     telex or by facsimile properly addressed in accordance with the addresses
     first above given or to such other addresses as the parties may at a later
     date advise.  The effective date of this notice shall be six (6) days after
     the date of sending such notice.

b)   This Agreement constitute the entire agreement between the parties
     concerning the subject matter hereof.  None of the terms of this Agreement
     shall be amended or modified except in writing signed by the parties
     hereto.  The headings used in this Agreement are only meant for easy
     reading of the Agreement.

                                       9
<PAGE>

c)   Provisions of this Agreement are separate and divisible and the invalidity
     or unenforceability of any part shall not affect the validity or
     enforceability of any remaining part or parts, all of which shall remain in
     full force and effect.  However, the parties agree to substitute any
     invalid or unenforceable provision by valid and enforceable arrangement
     which achieves to the greatest extent possible the financial balance and
     mutual understanding already established between the parties.

SIXTEENTH -  Any dispute, controversy or difference that may arise from the
-----------
interpretation or in connection with the present Agreement or as the compliance
of any other obligations contained herein, shall be submitted to arbitration
held in Barcelona (Spain), in the "Tribunal Arbitral de Barcelona" according to
its rules.  The award rendered in any such arbitration shall be final and
binding upon the parties hereto.

SEVENTEENTH -  The parties agree that the present document is a commercial
-------------
agreement and is ruled by the Clauses contained herein, and shall be governed by
the laws of Spain, by Spanish commercial usage or, in its case, by the Spanish
Civil Code.

In witness whereof, the present Agreement is signed in duplicate in the place
and date first written above.

INSTITUTO GRIFOLS, S.A.                  SERACARE INC.

/s/ Javier Jorba Ribes                   /s/ Barry D. Plost

                                       10
<PAGE>

                            LIST OF OMITTED ANNEXES

The following Annexes to the Albumin Supply Agreement have been omitted from
this Exhibit and shall be furnished to the Commission upon request:

Annex                    Document
-----                    --------

2                        USA Package Insert

3                        Human Albumin as Raw Material

5                        Shipment Information

6                        Confidential Disclosure Agreement

<PAGE>

                                    ANNEX 1

                                      ***

_________________________
*** Confidential information omitted and filed separately with the Securities
and Exchange Commission.

<PAGE>

                                    ANNEX 4

                             HUMAN ALBUMIN GRIFOLS

                              QUANTITIES AND PRICE

-  The quantities established for the year 1999 will be in the range of *** -
   *** vials per month.

-  Product price:

-        Human Albumin Grifols at *** per gram FOB Barcelona.

_________________________
-  *** Confidential information omitted and filed separately with the
   Securities and Exchange Commission.

                                       1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}]]